Navigating success during a rare disease product launch

In this video, experts Kapil Raina, Chris Zealey, and Brian Williams, explore insights on successfully launching products in rare disease markets.

Part 3: Navigating success during a rare disease product launch

The video outlines key success factors in rare disease markets through the five P's: People, Product, Payers, Promotion, and Placement. Watch here.

Part 2: Navigating success during a rare disease product launch

Gain insights from Chief Commercial Officers on launching in the rare disease market. Watch here.

Medical Affairs

Redefining the Treatment Paradigm in Mental Health

Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.

Medical Affairs

Pioneering Treatment Paradigm in Neurology

Discover how we assisted our client in positioning their therapy for optimal impact in the evolving landscape of steroid reduction and global treatment strategies.

Medical Affairs

Strategic Repositioning of a GI Market Leader Amidst Evolving Market Dynamics

Explore how we analyzed and refined our client's drug positioning across multiple indications to ensure market alignment and strategic coherence. Read the case study.

Medical Affairs

Communication Strategy for Novel MOA in Neurological Disorder

Our client aimed to apply a proven molecule to a new neurological disorder. We helped create a compelling narrative and cost-effective strategy to boost ROI. Read the case study.

Medical Affairs

Establishing the Scientific Stories of Novel Gene Therapies

Learn how we guided our client through early-stage clinical trials and competitive pressures to craft a compelling scientific narrative. Read the case study.

Medical Affairs

Strategic Launch in a Rare Hematologic Disease

Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.

Market Access

Value-Based Contracting Strategy and Playbook

We helped our major pharmaceutical client equip it organization to offer value-based contracts to support access for a new specialty drug. Read the case study.

Market Access

Reimbursement Strategy for Ophthalmic Insert

Discover how our tailored reimbursement strategy propelled a small biotech's innovative ophthalmic product to exceed launch forecasts by 60% in patient treatment.

Market Access

Communicating Value to Payers for New Auto-Immune Product

We helped a biopharma company design a compelling payer value story presentation for its new auto-immune product

Market Access

Economic Model Quantifying Rx to OTC Availability

We partnered with our client to establish a narrative that increased availability results in improvements in health outcomes and downstream cost savings. Read the case study.

Market Access

Evidence Generation Strategy – Cystic Fibrosis Asset/COPD

We helped a client’s new product team plan their US and EU access strategies for a novel compound with potential in both rare and more common respiratory conditions. Read the case study.

Market Access

Preparing for 2025: Financial and Operational Challenges of the Inflation Reduction Act

Essential Strategies for Manufacturers to Adapt Financially and Operationally Amidst Evolving Regulatory Landscapes and Market Pressures. Read the article to find out more.

Market Access

The Inflation Reduction Act: Updates and Considerations for Pharmaceutical Manufacturers

The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.

Part 1: Navigating success during a rare disease product launch

Explore the rare disease landscape, focusing on patients' diagnostic and treatment challenges, competitive dynamics, and tailored launch strategies.

Medical Affairs

Enhancing Manuscripts for Top-Tier Journal Publication

We helped a clinical-stage genetic medicine company enhance their manuscript and figures to meet the high standards of a top scientific journal. Discover how our targeted narrative refinement and figure enhancement led to their research being featured in a prestigious journal with an impact factor of 4.6.

Insights and Analytics

Competitor Analysis for Gene Therapy

A prominent pharmaceutical company launching its first to market gene therapy in a rare disease was seeking to enhance its market position and reimbursement approach.

Part 4: Finding an Experienced Strategic Partner for Commercial Drug Launch (Video)

In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.

Part 3: Leveraging a Proven Framework in the Drug Launch Process (Video)

Part 1: Value of Phase 2 Commercial Perspective for Drug Developments (VIDEO)

Part 2: Creating Credible Forecasts for Drug Development (Video)

Launching Life Science Brands: A Conversation with Experts on Commercial Readiness (VIDEO)

Market Access

New AMCP Dossier Format 5.0 Released

Learn key changes in the AMCP Dossier 5.0 format.

Launch Excellence

Co-commercialization Case Study for a First Oncology Launch

A mid-sized global pharmaceutical organization entered a co-commercialization agreement with a top-10 pharmaceutical organization to launch its first product in oncology.

Market Access

Are you prepared for the Medicaid AMP cap removal starting January 1, 2024?

Currently, Medicaid rebates paid by drug manufacturers are capped at the quarterly Average Manufacturer’s Price (AMP) for each drug/biologic. The removal of the cap means ...

Patient Services

Patient Services Launch Diagnostic

Support programs have the power to drive patients to start, stay and succeed on therapy. These programs and the best practices that drive patient experience and access are critical to success.

Launch Excellence

Navigating a Drug Launch: Part 4 – The Launch Plan

Today there is a laser focus on product performance out of the gate, so there is a lot of pressure to get it right. This means pharma companies need to make sure that they have the right launch team in place before putting together the structure and tactics in their launch plans. Read to learn more.

Launch Excellence

Navigating a Drug Launch: Part 3 – How to execute

How can reps engage physicians beyond office visits in our digital world? Ultimately, this is what the launch teams need to answer when developing the ‘how to execute’ portion of their strategies.

Launch Excellence

Navigating a Drug Launch: Part 2 – How to Win

Pharma companies that have product launches that repeatedly perform beyond expectations know how to develop vision and positioning, create a brand strategy with notable differentiation, and focus on building superior customer experiences. Learn more.

Launch Excellence

Navigating a Drug Launch: Part 1 – Where to Play?

At Herspiegel, we have partnered with biotech and pharma companies big and small and have successfully brought millions of dollars worth of drugs, devices, and treatments to market. But before we get a product out the door, we help launch teams navigate their go-to-market strategies.

Market Access

Evidence Generation Strategy for a New Drug Formulation

A global pharmaceutical company worked with us to plan their European Union (EU) access strategy for a novel oncolytic drug based on a new formulation. Read the case study.

Market Access

Payer Value Proposition Development in a Crowded Disease Space

Our client, a mid-sized biopharmaceutical company, aimed to introduce a new asset into the highly competitive Parkinson's disease category. Read the case study.

Market Access

Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices

Read the article about the cost and supply challenges leading to Hospitals needing to start their own drug companies to lower generic drug prices.

Launch Excellence

FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers

Read about key lifecycle challenges for Biologic Manufacturers in this article.

Cell and Gene Therapy Commercialization Innovations

In this whitepaper, you will discover: The four most common challenges in cell and gene therapy commercialization. Methods to address common product launch challenges. Insights to accelerate and de-risk launch for cell and gene therapy treatments. Read more.

Launch Excellence

Complete Response Letters are Increasing

Complete Response Letters (CRLs) are increasing. How are pharma companies preparing? Read more.

Market Access

Government Intervention into Drug Pricing: Part Two

In this post, we discuss different approaches that aim to incite competition between branded and generic drug products, as well as an example demonstrating the potential impact of these policies.

Market Access

Government Intervention into Drug Pricing: Part One

This is the first in a four-part series where we will explore the issue of government intervention in drug costs. In this first post, we introduce a few commonly mentioned tactics, two of which we will dig deeper into in subsequent posts.

Medical Affairs

Development of a Scientific Platform for Biotech Client

Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.

Medical Affairs

KOL Identification and Engagement Planning in Rare Disease Clinical Development

Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.

Medical Affairs

Unveiling Insights: How KOLs Shaped a Groundbreaking Therapy’s Journey

A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.

Roadmap to De-risk Commercialization of a Rare Disease Product

Explore Herspiegel's expert strategies for successful rare disease launches, from tech innovation to market responsiveness. Learn more now.

Market Access

CMS Announces First Drugs for Price Negotiations

The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.

Market Access

CMS Price Negotiations – Data Submission Update

Since CMS announced the first ten drugs selected for price negotiation on August 29th, 2023, primary manufacturers had until October 1st, 2023, to sign agreements to participate in the Price Negotiation Program. Read the article to find out more.

Market Access

Inflation Reduction Act Impacts: Navigating the New Landscape

The IRA will make many improvements to the Medicare program overall, and many on the pharmaceutical side have been mainly focused on preparing for the Medicare Drug Price Negotiation Program. Download this paper to understand the current timelines and guidance.

Navigating a Drug Launch

Master drug launch success! Herspiegel shares 4-part blog series on de-risking launch plans. Tap into our go-to-market model now.

The Importance of Building a Strong Portfolio of Products with Co-Positioning

Maximize portfolio impact! Learn key co-positioning strategies for products in our latest whitepaper. Boost performance now.

Articles

Case Studies

White Papers

All Resources

267.759.2130